NCT00493766View on ClinicalTrials.gov

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2008

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

LBH589

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center, New York

27705

Duke University Medical Center, Durham

63110

Washing University School of Medicine, St Louis

89135

Nevada Cancer Institute, Las Vegas

02115-6-84

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY